Brand Name | Status | Last Update |
---|---|---|
afinitor | New Drug Application | 2025-01-28 |
everolimus | ANDA | 2050-01-01 |
torpenz | ANDA | 2024-11-18 |
zortress | New Drug Application | 2025-01-03 |
Expiration | Code | ||
---|---|---|---|
EVEROLIMUS, AFINITOR DISPERZ, NOVARTIS PHARM | |||
2025-04-10 | ODE-169 | ||
EVEROLIMUS, AFINITOR, NOVARTIS | |||
2023-02-26 | ODE-108 |
Code | Description |
---|---|
J7527 | Everolimus, oral, 0.25 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 13 | 34 | 8 | 3 | 7 | 60 |
Carcinoma | D002277 | — | C80.0 | 9 | 32 | 2 | 3 | 2 | 44 |
Kidney transplantation | D016030 | — | — | 1 | 3 | 14 | 20 | — | 38 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 13 | 21 | 1 | 3 | 4 | 38 |
Neoplasms | D009369 | — | C80 | 22 | 13 | 1 | 2 | 1 | 36 |
Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 11 | 11 | 3 | 3 | 2 | 28 |
Liver transplantation | D016031 | EFO_0010682 | — | — | 1 | 11 | 2 | 1 | 14 |
Lung neoplasms | D008175 | — | C34.90 | 10 | 2 | — | 1 | — | 13 |
Tuberous sclerosis | D014402 | — | Q85.1 | 4 | 7 | 4 | 2 | — | 13 |
Sclerosis | D012598 | — | — | 4 | 7 | 4 | 2 | — | 13 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Lymphoma | D008223 | — | C85.9 | 6 | 8 | 1 | — | — | 13 |
Astrocytoma | D001254 | EFO_0000271 | — | 2 | 5 | 1 | — | — | 7 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 3 | 5 | 1 | — | — | 7 |
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 2 | 2 | 1 | — | — | 5 |
B-cell lymphoma | D016393 | — | — | 1 | 3 | 1 | — | — | 5 |
Carcinoid tumor | D002276 | — | D3A.00 | 3 | 2 | 1 | — | — | 5 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 2 | 1 | — | — | 4 |
Lymphangioleiomyomatosis | D018192 | — | J84.81 | 2 | 3 | 1 | — | — | 4 |
Stomatitis | D013280 | EFO_1001904 | K12.1 | — | 2 | 1 | — | — | 3 |
Mucositis | D052016 | EFO_1001898 | — | — | 2 | 1 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Kidney neoplasms | D007680 | EFO_0003865 | C64 | 7 | 8 | — | — | — | 14 |
Recurrence | D012008 | — | — | 5 | 6 | — | — | — | 11 |
Non-small-cell lung carcinoma | D002289 | — | — | 8 | 1 | — | — | — | 9 |
Colorectal neoplasms | D015179 | — | — | 6 | 7 | — | — | — | 9 |
Prostatic neoplasms | D011471 | — | C61 | 4 | 6 | — | — | — | 8 |
Head and neck neoplasms | D006258 | — | — | 5 | 5 | — | — | — | 8 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | 7 | — | — | — | 8 |
Glioma | D005910 | EFO_0000520 | — | 2 | 5 | — | — | — | 7 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 3 | 5 | — | — | — | 7 |
Sarcoma | D012509 | — | — | 2 | 4 | — | — | — | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Esophageal neoplasms | D004938 | — | C15 | 2 | — | — | — | — | 2 |
Multiple myeloma | D009101 | — | C90.0 | 2 | — | — | — | — | 2 |
Uterine cervical neoplasms | D002583 | — | — | 2 | — | — | — | — | 2 |
Brain stem neoplasms | D020295 | EFO_1001767 | — | 1 | — | — | — | — | 1 |
Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | — | 1 |
Follicular lymphoma | D008224 | — | C82 | 1 | — | — | — | — | 1 |
Nasopharyngeal carcinoma | D000077274 | — | — | 1 | — | — | — | — | 1 |
Adenoid cystic carcinoma | D003528 | — | — | 1 | — | — | — | — | 1 |
Ureteral neoplasms | D014516 | EFO_0003844 | C66 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 1 | 1 |
Drug common name | Everolimus |
INN | everolimus |
Description | Everolimus is a macrocyclic lactone that is rapamycin in which the hydroxy group attached to the cyclohexyl moiety has been converted into the corresponding 2-hydroxyethyl ether. It is an immunosuppressant and antineoplastic agent. It has a role as an antineoplastic agent, an immunosuppressive agent, a mTOR inhibitor, an anticoronaviral agent and a geroprotector. It is a primary alcohol, a secondary alcohol, an ether, a cyclic ketone, a cyclic acetal and a macrolide lactam. It is functionally related to a member of sirolimus. |
Classification | Small molecule |
Drug class | immunosuppressives |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C |
PDB | — |
CAS-ID | 159351-69-6 |
RxCUI | — |
ChEMBL ID | CHEMBL1908360 |
ChEBI ID | 68478 |
PubChem CID | 6442177 |
DrugBank | DB01590 |
UNII ID | 9HW64Q8G6G (ChemIDplus, GSRS) |